Dr. Clay Siegall is the co-founder, president, and CEO of Seattle Genetics. He also serves as the chairman of the board of the directors of the company. It is through his leadership that Seattle Genetics company has come up with diverse drug pipeline of antibodies targeting cancer treatments. Clay Siegall has played a role in raising finance and securing over $ 675 million.
Before founding Seattle Genetics, Dr.Siegall served at National Institute of Health, National Cancer Institute, and Bristol-Myers Squibb Pharmaceutical Research Institute. Clay was also part of the board of directors at Alder BioPharmaceutical. He has written over 70 publications and had 15 patents. He holds Ph.D. in Genetics from Washington University and also from the University of Maryland he has a B.S in Zoology.
Since 1998, Seattle Genetics company has been leading in manipulating, studying and packaging drugs. Seattle Genetics is a world of human antibodies. The power of the company`s human bodies dwells in their ability to connect with therapies. The manufactured antibodies deliver and produces a toxic payload to a cancer cell and destroy the cell from the inside.
Seattle Genetics Company has boosted its market value to almost $10 billion and has provided jobs to over 900 employees. It is one of the modern biotech companies in Washington. It is aiming to transform from biotech to a large pharmaceutical firm in the world. It has invested in research and marketing.
The company launched Adcetris drug which treats Hodgkin Lymphoma. A Lymphatic system cancer that sometimes can spread to other body organs. The company is now multi product and an oncology firm with several drugs pipelines. Seattle Genetics frequently focuses on the antibody-drug conjugate (ADC). ADC targets the human antigens the protein molecules which trigger the human immune system to produce antibodies that fight against diseases. These antibodies attack the cancer cell from inside delivering a toxic substance which kills the cell without damaging the healthy human cells. This kind of therapy reduces the collateral harm that can occur in normal cells during chemotherapy and radiation through the traditional approach.
In Seattle Genetics drug pipeline the second one is 33A which targets and cure myeloid leukemia (AML) it was studied after the death of four patients who suffered from AML. Though there are fewer cases of this disease, the treatments are readily available in Seattle Genetics. The third drug is 22ME which targets the bladder cancer and any other urothelial cancers while the fourth drug is LIVI which treats breast cancer.